Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited (IMMP) is a clinical-stage biotechnology leader pioneering LAG-3 immunotherapies for cancer and autoimmune diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Key resources include: Press releases detailing trial results for therapies like IMP321 and IMP701, financial disclosures from global exchanges, partnership announcements with major pharmaceutical collaborators, and scientific presentations demonstrating LAG-3 innovation. All content is sourced directly from company filings and verified channels.
Bookmark this page for streamlined access to Immutep's latest developments in immuno-oncology research, including updates from ongoing clinical programs and analyses of emerging therapeutic strategies. Check regularly for real-time insights into one of biotech's most active immunotherapy pipelines.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made significant strides in its clinical trials, successfully dosing the final HNSCC patient in Stage 2 of Part C of the TACTI-002 study. Recruitment has begun for both first and second line NSCLC patients in the trial. The Phase II EAT COVID trial has also advanced into its randomized segment. As of March 31, 2021, the company reported a strong cash position of $51.7 million, providing a runway beyond 2022. The company has bolstered intellectual property protections for its lead candidate, eftilagimod alpha, with a new patent granted.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a cash rebate of A$1,155,055 from the Australian Federal Government’s R&D tax incentive program. This rebate pertains to expenses from eligible R&D activities during the 2020 fiscal year, primarily focusing on the TACTI-mel and TACTI-002 clinical studies involving eftilagimod alpha (efti). With approval from AusIndustry, Immutep’s Australian and overseas activities related to TACTI-002 are eligible for this tax incentive for three years, using the funds to further its clinical trials.
Immutep Limited (NASDAQ: IMMP) announced that its lead candidate, eftilagimod alpha (efti), has received FDA Fast Track designation for first-line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This designation is based on promising data from its Phase II TACTI-002 trial, showing a 36% overall response rate. Additionally, preparations for the new Phase IIb TACTI-003 trial are advancing. Fast Track designation allows Immutep expedited development and review processes with the FDA, potentially leading to quicker patient access.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of patent number EP3317301 by the European Patent Office, covering combination therapies involving its LAG525 antibody and spartalizumab for cancer treatment. This patent, co-owned with Novartis AG, extends until July 28, 2036. LAG525 is evaluated in several clinical trials by Novartis, and Immutep stands to receive milestone and royalty payments from its development.
Immutep Limited announced that CEO Marc Voigt will participate in the Inaugural Emerging Growth Virtual Conference on March 17-19, 2021. Voigt is scheduled for a fireside chat with analyst Jason McCarthy on March 19 at 9:30 am EST. The conference features discussions with C-suite executives and live Q&A sessions.
Immutep focuses on developing immunotherapy treatments for cancer and autoimmune diseases, with their lead product candidate being eftilagimod alpha. The company is listed on the ASX (IMM) and NASDAQ (IMMP).
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced a new Phase IIb trial named TACTI-003 to evaluate the combination of its lead product eftilagimod alpha with MSD’s KEYTRUDA® in treating first-line head and neck squamous cell carcinoma (HNSCC). Expected to enroll its first patient by mid-2021, the trial will involve around 160 patients and aim to assess safety and efficacy compared to KEYTRUDA alone. HNSCC is a prevalent cancer with significant unmet medical needs, highlighting the importance of this study.
Immutep Limited (NASDAQ: IMMP) has announced the grant of a new patent (10,940,181) by the U.S. Patent & Trade Mark Office for methods of treating cancer using its lead immunotherapy candidate, eftilagimod alpha (efti), combined with a PD-1 pathway inhibitor such as pembrolizumab or nivolumab. The patent, valid until January 20, 2036, enhances the company's intellectual property and supports ongoing investments in clinical development. This announcement follows the grant of a parent patent in December 2020 and indicates further developments are underway, including additional divisional applications.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced an expansion of Part B in its TACTI-002 Phase II trial for second line Non-Small Cell Lung Cancer (NSCLC), following a positive safety and efficacy review. The study, conducted in collaboration with Merck & Co., aims to evaluate the combination of efti and KEYTRUDA® in multiple cancer types. Additional patient recruitment will include 13 more NSCLC patients in Stage 2 of Part B. This trial represents an opportunity to advance treatment options in oncology and reflects Immutep's commitment to immunotherapy development.
Immutep Limited has announced that its interim Overall Survival results from the Phase IIb AIPAC study will be presented at the San Antonio Breast Cancer Symposium 2020, scheduled for December 11. The AIPAC trial evaluates the combination of eftilagimod alpha and paclitaxel in HR-positive metastatic breast cancer patients. This presentation is a significant opportunity to showcase research at an esteemed international conference attended by over 90 countries. The poster will be available on Immutep's website post-event.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced new interim results from its Phase II TACTI-002 study, presented on September 17, 2020. The trial investigates the combination of eftilagimod alpha and KEYTRUDA in patients with resistant head and neck squamous cell carcinoma and non-small cell lung cancer. Significant findings include three complete responses and an improved median progression-free survival (PFS) of 4.3 months in HNSCC and 11.8 months in NSCLC. The trial continues enrollment, with 89 out of 109 participants recruited by the cut-off date of August 21, 2020.
